A Bayesian Network to Predict the Risk of Post Influenza Vaccination Guillain-Barré Syndrome: Development and Validation Study.


Journal

JMIR public health and surveillance
ISSN: 2369-2960
Titre abrégé: JMIR Public Health Surveill
Pays: Canada
ID NLM: 101669345

Informations de publication

Date de publication:
25 03 2022
Historique:
received: 10 11 2020
accepted: 02 02 2022
revised: 27 12 2020
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 13 4 2022
Statut: epublish

Résumé

Identifying the key factors of Guillain-Barré syndrome (GBS) and predicting its occurrence are vital for improving the prognosis of patients with GBS. However, there are scarcely any publications on a forewarning model of GBS. A Bayesian network (BN) model, which is known to be an accurate, interpretable, and interaction-sensitive graph model in many similar domains, is worth trying in GBS risk prediction. The aim of this study is to determine the most significant factors of GBS and further develop and validate a BN model for predicting GBS risk. Large-scale influenza vaccine postmarketing surveillance data, including 79,165 US (obtained from the Vaccine Adverse Event Reporting System between 1990 and 2017) and 12,495 European (obtained from the EudraVigilance system between 2003 and 2016) adverse events (AEs) reports, were extracted for model development and validation. GBS, age, gender, and the top 50 prevalent AEs were included for initial BN construction using the R package bnlearn. Age, gender, and 10 AEs were identified as the most significant factors of GBS. The posttest probability of GBS suggested that male vaccinees aged 50-64 years and without erythema should be on the alert or be warned by clinicians about an increased risk of GBS, especially when they also experience symptoms of asthenia, hypesthesia, muscular weakness, or paresthesia. The established BN model achieved an area under the receiver operating characteristic curve of 0.866 (95% CI 0.865-0.867), sensitivity of 0.752 (95% CI 0.749-0.756), specificity of 0.882 (95% CI 0.879-0.885), and accuracy of 0.882 (95% CI 0.879-0.884) for predicting GBS risk during the internal validation and obtained values of 0.829, 0.673, 0.854, and 0.843 for area under the receiver operating characteristic curve, sensitivity, specificity, and accuracy, respectively, during the external validation. The findings of this study illustrated that a BN model can effectively identify the most significant factors of GBS, improve understanding of the complex interactions among different postvaccination symptoms through its graphical representation, and accurately predict the risk of GBS. The established BN model could further assist clinical decision-making by providing an estimated risk of GBS for a specific vaccinee or be developed into an open-access platform for vaccinees' self-monitoring.

Sections du résumé

BACKGROUND
Identifying the key factors of Guillain-Barré syndrome (GBS) and predicting its occurrence are vital for improving the prognosis of patients with GBS. However, there are scarcely any publications on a forewarning model of GBS. A Bayesian network (BN) model, which is known to be an accurate, interpretable, and interaction-sensitive graph model in many similar domains, is worth trying in GBS risk prediction.
OBJECTIVE
The aim of this study is to determine the most significant factors of GBS and further develop and validate a BN model for predicting GBS risk.
METHODS
Large-scale influenza vaccine postmarketing surveillance data, including 79,165 US (obtained from the Vaccine Adverse Event Reporting System between 1990 and 2017) and 12,495 European (obtained from the EudraVigilance system between 2003 and 2016) adverse events (AEs) reports, were extracted for model development and validation. GBS, age, gender, and the top 50 prevalent AEs were included for initial BN construction using the R package bnlearn.
RESULTS
Age, gender, and 10 AEs were identified as the most significant factors of GBS. The posttest probability of GBS suggested that male vaccinees aged 50-64 years and without erythema should be on the alert or be warned by clinicians about an increased risk of GBS, especially when they also experience symptoms of asthenia, hypesthesia, muscular weakness, or paresthesia. The established BN model achieved an area under the receiver operating characteristic curve of 0.866 (95% CI 0.865-0.867), sensitivity of 0.752 (95% CI 0.749-0.756), specificity of 0.882 (95% CI 0.879-0.885), and accuracy of 0.882 (95% CI 0.879-0.884) for predicting GBS risk during the internal validation and obtained values of 0.829, 0.673, 0.854, and 0.843 for area under the receiver operating characteristic curve, sensitivity, specificity, and accuracy, respectively, during the external validation.
CONCLUSIONS
The findings of this study illustrated that a BN model can effectively identify the most significant factors of GBS, improve understanding of the complex interactions among different postvaccination symptoms through its graphical representation, and accurately predict the risk of GBS. The established BN model could further assist clinical decision-making by providing an estimated risk of GBS for a specific vaccinee or be developed into an open-access platform for vaccinees' self-monitoring.

Identifiants

pubmed: 35333192
pii: v8i3e25658
doi: 10.2196/25658
pmc: PMC8994148
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25658

Informations de copyright

©Yun Huang, Chongliang Luo, Ying Jiang, Jingcheng Du, Cui Tao, Yong Chen, Yuantao Hao. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 25.03.2022.

Références

J Neurol Neurosurg Psychiatry. 2012 Jul;83(7):711-8
pubmed: 22566597
Pharmacoepidemiol Drug Saf. 2021 May;30(5):602-609
pubmed: 33533072
BMJ. 2015 Jan 07;350:g7594
pubmed: 25569120
Pediatr Neurol. 2018 Jul;84:56
pubmed: 29859718
Autoimmun Rev. 2017 Jan;16(1):96-101
pubmed: 27666816
J Surg Res. 2017 Mar;209:168-173
pubmed: 28032554
Eur J Neurol. 2000 Jan;7(1):11-6
pubmed: 10809910
Am J Epidemiol. 1979 Aug;110(2):105-23
pubmed: 463869
Acta Neurol Scand. 1994 Apr;89(4):287-92
pubmed: 8042448
Neurology. 2011 Mar 15;76(11):968-75
pubmed: 21403108
Neurology. 2003 Apr 8;60(7):1146-50
pubmed: 12682322
Lancet. 2016 Aug 13;388(10045):717-27
pubmed: 26948435
Nature. 2015 May 28;521(7553):452-9
pubmed: 26017444
Eur J Case Rep Intern Med. 2020 Jan 27;7(2):001387
pubmed: 32133309
Front Neurol. 2018 Sep 07;9:699
pubmed: 30245663
Neurol Sci. 2004 Jun;25(2):57-65
pubmed: 15221623
JAMA. 2004 Nov 24;292(20):2478-81
pubmed: 15562126
N Engl J Med. 1998 Dec 17;339(25):1797-802
pubmed: 9854114
Med Phys. 2015 May;42(5):2421-30
pubmed: 25979036
Lancet. 2013 Apr 27;381(9876):1461-8
pubmed: 23498095
Ann Neurol. 2010 Jun;67(6):781-7
pubmed: 20517939
Neuroepidemiology. 2011;36(2):123-33
pubmed: 21422765
J Neurol Neurosurg Psychiatry. 1998 Aug;65(2):218-24
pubmed: 9703176
Neurol Sci. 2019 Nov;40(11):2403-2404
pubmed: 31093786
Clin Infect Dis. 2009 Jan 1;48(1):48-56
pubmed: 19025491
Arch Neurol. 2005 Aug;62(8):1194-8
pubmed: 16087757
Lancet Neurol. 2007 Jul;6(7):589-94
pubmed: 17537676
Stat Methods Med Res. 2015 Dec;24(6):836-55
pubmed: 22143403
J Biomed Inform. 2018 Dec;88:1-10
pubmed: 30399432
Curr Infect Dis Rep. 2011 Aug;13(4):387-98
pubmed: 21681501
Eur Neurol. 2001;46(2):83-91
pubmed: 11528157
Lancet Infect Dis. 2010 Sep;10(9):643-51
pubmed: 20797646

Auteurs

Yun Huang (Y)

Department of Medical Statistics, Sun Yat-Sen University, Guangzhou, China.
Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China.

Chongliang Luo (C)

Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States.
Division of Public Health Sciences, Washington University School of Medicine in St. Louis, St. Louis, MO, United States.

Ying Jiang (Y)

Department of Neurology and Multiple Sclerosis Research Center, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.

Jingcheng Du (J)

School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, United States.

Cui Tao (C)

School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, United States.

Yong Chen (Y)

Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States.

Yuantao Hao (Y)

Department of Medical Statistics, Sun Yat-Sen University, Guangzhou, China.
Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH